Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

Authors not listed

Neurogen Biomarking LLC · 2025

Abstract

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-08 MST

Cite this

APA
Anonymous. (2025). Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device. <em>Neurogen Biomarking LLC</em>. https://clinicaltrials.gov/study/NCT07701161
Vancouver
Anonymous. Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device. Neurogen Biomarking LLC. 2025.
BibTeX
@misc{anon2025Develo, title = {Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device}, author = {Anonymous}, journal = {Neurogen Biomarking LLC}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings